[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621264":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":56,"collaborators":25,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Kafrelsheikh University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"\"Comparative Outcomes of Mucosal Reset (Reboot) IN CRSWNP","EXPERIMENTAL","The first group will undergo Reboot operation\" Complete removal of inflamed mucosa to periosteum\"",[13],"Device: Reboot operation\" Complete removal of inflamed mucosa to periosteum\"",{"label":15,"type":10,"description":16,"interventionNames":17},"Complete Sinusotomy (Full House FESS IN CRSWNP","the second group will have a conventional FESS operation \" Mucosal preservation where healthy\"",[18],"Device: endoscopic nasal operation",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","endoscopic nasal operation",". conventional FESS operation \"",[15],null,{"type":21,"name":27,"description":27,"armGroupLabels":28,"otherNames":25},"Reboot operation\" Complete removal of inflamed mucosa to periosteum\"",[9],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Amr Maher Shady Kafr Elsheikh Hospital University, Doctor","CONTACT","0201060485163","amrshady00@gmail.com",{"name":36,"role":32,"phone":25,"phoneExt":25,"email":37},"Saad Elzayat Kafr Elsheikh Hospital University, professor","saad_hilmy@med.kfs.edu.eg",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Kafrelsheikh Faculty of Medicine","RECRUITING","Egypt","Kafrelsheikh","33155.","Canada","CA",{"type":48,"coordinates":49},"Point",[50,51],-79.3046,44.27004,{"lat":51,"lon":50},[54],{"name":25,"role":32,"phone":55,"phoneExt":25,"email":25},"0473109517",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Amr Mahr Shady","resident","100621264","th-study-wants-to-compare-the-best-technique-for-sinus-operation-in-crswnp-100621264",false,"NCT07368361","Th Study Wants to Compare the Best Technique for Sinus Operation in CRSWNP","\"Comparative Outcomes of Mucosal Reset (Reboot) Versus Complete Sinusotomy (Full House FESS) in CRSwNP: A Prospective Study","REBOOT","Inclusion Criteria:Patients above the age of 18 years presenting with recurrent refractory CRSwNP (failed ≥1 biologic\u002Fprior FESS), Type-2 endotype confirmation (blood\u002Ftissue eosinophilia, IgE ≥100 IU\u002FmL), Lund-Mackay CT score ≥10 will be included in the study.\n\nExclusion Criteria:\n\neosinophilic granulomatosis with polyangiitis (EGPA) or severe systemic diseases (except controlled asthma or NSAID-exacerbated respiratory disease), neoplasms, vasoconstrictor abuse (e.g., oxymetazoline dependence), unilateral nasal inflammatory disease, bilateral inflammatory disease without polyps, or treatment with monoclonal antibodies in the past 12 months, Patients younger than 18 years of age and patients are unfit for general anesthesia.","ALL","18 Years","75 Years",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76],"NA","This randomized controlled trial aims to compare the efficacy and safety of reboot surgery versus conventional full house FESS in patients with refractory CRSwNP, focusing on:\n\n1\\. Primary Outcome:\n\n* Compare 24-month recurrence rates (defined as endoscopic polyp score ≥2) 2. Secondary Outcomes:\n* Recurrence-free survival (time to first recurrence), Quality of life improvement (SNOT-22 scores), Reduction in systemic corticosteroid use, Complication rates (synechiae, bleeding, infection) and Cost-effectiveness of each approach",[79],"CRSWNP",[81],"REBOOT, SINUSOTOMY, FULL HOUSE FESS, CRSWNP","2026-05-23",{"date":84,"type":85},"2026-05-28","ACTUAL",{"date":87,"type":85},"2026-01-01",{"date":89,"type":73},"2026-09-01",{"name":5,"class":6},1]